BRD4 Degradation by PROTACs® Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in DLBCL
BRD4 Degraders Produce Long-Lasting Loss of BRD4 Protein and Robust Efficacy in Burkitt’s Lymphoma, Multiple Myeloma and Prostate Cancer Cells
